Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study
Allergy · 2025
DOI: 10.1111/all.70071 ↗At a glance
Multizentrische Studie in Allergy, 2025. Written by Santi Nolasco and 19 co-authors. Institution: Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Major MEDLINE topics: Asthma, Receptors, Adrenergic, beta-2, Antibodies, Monoclonal, Humanized, Polymorphism, Single Nucleotide. 68 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background β 2 ‐adrenergic signaling promotes airway smooth muscle relaxation and limits the release of pro‐inflammatory mediators by immune cells. The rs1042713 polymorphism encodes a glycine‐to‐arginine substitution (Arg16Gly) that enhances β 2 ‐receptor downregulation. We investigated the association of this polymorphism with the risk of severe eosinophilic asthma and its impact on the long‐term effectiveness of mepolizumab and clinical remission.
Methods
Genotypes from 102 patients with severe eosinophilic asthma receiving mepolizumab were compared with those from 31 individuals with mild asthma and 20 healthy controls. The severe‐asthma cohort was followed for up to 24 months, and clinical data were collected at baseline and after 3, 6, 12, and 24 months of treatment. Analyses were stratified by Arg/Arg, Arg/Gly, and Gly/Gly genotypes.
Results
Each additional Arg16 allele increased the odds of severe eosinophilic asthma by 2.61‐fold (95% CI 1.48–4.59; p = 0.0001) relative to mild asthma and by 3.61‐fold (95% CI 1.78–7.35; p < 0.0001) relative to healthy controls. Over 24 months of mepolizumab treatment, Arg/Arg patients had an increased risk of exacerbations (HR 2.3 [95% CI 1.03–5.20]; p = 0.0414) and poorer asthma control compared with Gly/Gly patients (ACT ≥ 20: 72.4% vs. 100%, p = 0.0308). Gly/Gly patients also experienced less decline in lung function. By month 24, each additional Gly16 allele increased the odds of achieving clinical remission by 2.86‐fold (95% CI 1.20–6.81; p = 0.0170), defined as no annual exacerbations, no OCS, and ACT ≥ 20, and by 3.06‐fold (95% CI 1.34–6.96; p = 0.0080) when including an FEV 1 decline ≤ 5% from baseline.
Conclusions
The Arg16 allele of the rs1042713 polymorphism increases the risk of severe eosinophilic asthma and may reduce the long‐term efficacy of mepolizumab, whereas the Gly16 allele appears to confer better outcomes and higher remission rates.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
- Respiratory Medicine Unit, Policlinico "G. Rodolico-San Marco" University Hospital, Catania, Italy.
- Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.
- Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
- Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
ORCID profiles: Santi Nolasco, Andrea Portacci, Angelantonio Maglio, Vitaliano Nicola Quaranta
Cite
APA
Nolasco, S., Fagone, E., Campisi, R., Portacci, A., Scioscia, G., Pelaia, C., Maglio, A., Candia, C., Quaranta, V. N., Carrieri, I., Saglia, A., Vatrella, A., Pelaia, G., Vancheri, C., Foschino Barbaro, M. P., D'Amato, M., Carpagnano, G. E., Crimi, N., Crimi, C., & Southern Italy Network on Severe Asthma Therapy (2025). Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study. Allergy. https://doi.org/10.1111/all.70071
Vancouver
Nolasco S, Fagone E, Campisi R, Portacci A, Scioscia G, Pelaia C, et al. Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study. Allergy. 2025. doi:10.1111/all.70071
BibTeX
@article{Nolasco2025,
author = {Nolasco, Santi and Fagone, Evelina and Campisi, Raffaele and Portacci, Andrea and Scioscia, Giulia and Pelaia, Corrado and Maglio, Angelantonio and Candia, Claudio and Quaranta, Vitaliano Nicola and Carrieri, Isabella and Saglia, Alessandro and Vatrella, Alessandro and Pelaia, Girolamo and Vancheri, Carlo and Foschino Barbaro, Maria Pia and D'Amato, Maria and Carpagnano, Giovanna Elisiana and Crimi, Nunzio and Crimi, Claudia and Southern Italy Network on Severe Asthma Therapy, Southern Italy Network on Severe Asthma Therapy},
title = {Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.70071}
}
EUVIMED